DENTSPLY SIRONA

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic and orthodontic dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dentsply Sirona (XRAY) exceeds Q4 expectations, focuses on innovation

Dentsply Sirona (XRAY) reported strong financial performance in Q4 2022, with a strategic focus on digitalization and innovation. Despite challenges in organic sales and supply chain constraints, the company aims for margin improvement and growth opportunities through investments and pricing strategies. Restructuring efforts and acquisitions are set to drive profitability and market share gains.

Dentsply Sirona reports robust Q1 growth, eyes digital innovation

Dentsply Sirona's strong Q1 performance driven by Consumables and Aligners segments.
Challenges include mixed regional performance and cautious outlook on equipment demand.
Opportunities lie in digitalization, DSO partnerships, and growth in China and EPS targets.
Overall, a positive outlook with strategic focus on innovation and customer experience.

Dentsply Sirona exceeds Q2 expectations, eyes growth amid challenges

Dentsply Sirona reported strong financial performance in Q2 2023, exceeding expectations and raising full-year outlook across key financial metrics.
The company's strategic focus on growth, profitability, and digitalization, coupled with investments in key regions and product innovation, positions it for sustained success.
While facing challenges in certain markets and operational areas, Dentsply Sirona remains optimistic about opportunities for growth, innovation, and value creation in the dental industry.
Overall, Dentsply Sirona's performance highlights operational strengths, market positioning, and a forward-looking approach to driving shareholder value and market expansion.

DENTSPLY SIRONA reports mixed Q3 results, focuses on innovation and growth

DENTSPLY SIRONA's Q3 performance showed mixed results with challenges in certain markets but strength in key segments like CAD/CAM and Aligners.
The company is focused on driving value through innovation, maintaining a commitment to long-term plans, and navigating external challenges with confidence.
Despite headwinds, DENTSPLY SIRONA remains within guidance range for the year, with a strategic focus on volume growth and market expansion opportunities.

DENTSPLY SIRONA anticipates double-digit EPS growth in 2024

DENTSPLY SIRONA's Q4 2023 performance showed growth in key segments, with strategic initiatives set for 2024 as an inflection year for double-digit EPS growth.
The company is focusing on innovation, SKU optimization, and operational efficiency to drive profitability and revenue growth.
Challenges lie in certain segments and the need for organic growth normalization by 2025, but opportunities exist in new product launches and margin expansion.
Overall, DENTSPLY SIRONA is poised for accelerated profitable growth, with 2024 expected to be a pivotal year for improved performance.

DENTSPLY SIRONA reports mixed Q1 performance amidst innovation focus

DENTSPLY SIRONA navigated challenges in Q1 with a focus on innovation, sustainability, and strategic updates. While facing headwinds in certain segments and markets, the company aims to capitalize on growth opportunities through product launches and strategic initiatives.

DENTSPLY Sirona navigates revenue decline with strategic restructuring plans

DENTSPLY Sirona's Q2 performance reflects revenue decline and margin contraction, prompting strategic restructuring and focus on customer-centric initiatives. While facing challenges from macroeconomic factors and restructuring impacts, the company aims to leverage opportunities in shareholder returns and market dynamics to drive growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

Dentsply Sirona's next-generation intraoral scanner opens a new era of digital patient care, allowing scanning directly to the cloud on any internet-connected device. Cloud-native, wireless, and highly versatile — this is Primescan 2.

Dentsply Sirona presents Primescan® 2 powered by DS Core: The first cloud-native intraoral scanning solution

Dublin, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The "Brazil Digital Dentistry Market Size, Share & Trends Analysis | 2024-2030 | MedSuite | Includes: Dental CAD/CAM Devices, Dental CAD/CAM Materials (Discs & Blocks), Dental 3D Printers, and 2 more" report has been added to ResearchAndMarkets.com's offering. In 2023, the Brazilian digital dentistry market was valued at nearly $462 million. It is expected to grow at a CAGR of 2.9%, reaching over $564 million by the end of the forecast period. The comprehensive report on the Brazilian market for digital dentistry covers various segments, including computer-aided design/computer-aided manufacturing (CAD/CAM) devices, CAD/CAM materials, dental 3D printers, dental 3D printer materials, and CAD/CAM software. Currently, the majority of Brazil's digital dentistry device market share is controlled by Dentsply Sirona, Amann Girrbach, and Ivoclar.

Brazil Digital Dentistry Market Size, Share & Trends Analysis 2024-2030: Dentsply Sirona, Amann Girrbach and Ivoclar Dominate the Brazilian Digital Dentistry Market

CHARLOTTE, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Executive Vice President and Chief Financial Officer Glenn Coleman will resign effective November 7, 2024, to assume an executive position at another public company.

Dentsply Sirona Initiates Search for New CFO

Explore how Dentsply's (XRAY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Interpreting Dentsply (XRAY) International Revenue Trends

DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q2 2024 Earnings Call July 31, 2024 8:30 AM ET Company Participants Andrea Daley - Investor Relations Simon Campion - Chief Executive Officer Glenn Coleman - Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair Dylan Finley - UBS David Saxon - Needham & Company Elizabeth Anderson - Evercore ISI Dan Clark - Leerink Jon Block - Stifel Jeff Johnson - Baird Jason Bednar - Piper Sandler Allen Lutz - BoA Operator Good day and thank you for standing by. Welcome to the DENTSPLY SIRONA Earnings Conference Call.

DENTSPLY SIRONA Inc. (XRAY) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Dentsply (XRAY) Reports Q2 Earnings: What Key Metrics Have to Say

DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.

DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y

Dentsply International (XRAY) came out with quarterly earnings of $0.49 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.51 per share a year ago.

Dentsply International (XRAY) Q2 Earnings and Revenues Lag Estimates

CHARLOTTE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2024.

Dentsply Sirona Reports Second Quarter 2024 Results and Announces Second Phase of Transformation

Cencora Inc

GE HealthCare Technologies Inc

Glaukos

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

Dentsply Sirona Inc Investors Are Encouraged By The Schall Law Firm To Join The XRAY Inquiry

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

DENTSPLY SIRONA Inc Investors Are Urged By The Schall Law Firm To Participate In The XRAY Inquiry

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

Dentsply Sirona Inc Investors Are Called Upon By The Schall Law Firm To Join The Xray Inquiry

LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

DENTSPLY SIRONA Inc Investors Are Called Upon By The Schall Law Firm To Join The XRAY Inquiry

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

Dublin, July 25, 2024 (GLOBE NEWSWIRE) -- The "Columbia Dental Prosthetics Market Size, Share & Trends Analysis | 2024-2030 | MedSuite | Includes: Crowns and Bridges, Inlays and Onlays, and 4 more" report has been added to ResearchAndMarkets.com's offering. In 2023, the dental prosthetics market in Colombia reached a valuation of more than $132 million. This market is projected to grow at a compound annual growth rate (CAGR) of 5.1%, nearing $188 million in the forecast period. The comprehensive report on the Colombian dental prosthetics market covers various segments, including crowns and bridges, dentures, denture teeth, CAD/CAM prosthetics, inlays and onlays, and veneers. DATA TYPES INCLUDED

Columbia Dental Prosthetics Market Analysis Report 2024-2030, Featuring Key Players Dentsply Sirona, Ivoclar, New Stetic and VITA

Dublin, July 22, 2024 (GLOBE NEWSWIRE) -- The "Brazil Dental Prosthetics Market Size, Share & Trends Analysis | 2024-2030 | MedSuite | Includes: Crowns and Bridges, Inlays and Onlays, and 4 more" report has been added to ResearchAndMarkets.com's offering. In 2023, the Brazilian dental prosthetics market was valued at more than $10.2 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 5.2%, reaching nearly $14.7 billion over the forecast period. The comprehensive report on Brazil's dental prosthetics market encompasses various segments, including crowns and bridges, dentures, denture teeth, CAD/CAM prosthetics, inlays and onlays, and veneers. DATA TYPES INCLUDED

Brazil Dental Prosthetics Market Size, Share & Trends Analysis 2024-2030, Featuring Dentsply Sirona, Ivoclar, VITA and Kulzer

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

DENTSPLY SIRONA Inc Stakeholders Are Invited By The Schall Law Firm To Participate In The XRAY Probe

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

The Schall Law Firm Calls Upon DENTSPLY SIRONA Inc Investors To Join The XRAY Investigation.

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

DENTSPLY SIRONA Inc Investors Are Called Upon By The Schall Law Firm To Participate In The XRAY Inquiry

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

Investors Of DENTSPLY SIRONA Inc Are Invited By The Schall Law Firm To Join The XRAY Investigation

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

The Schall Law Firm Invites Investors Of DENTSPLY SIRONA Inc To Participate In The XRAY Investigation

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

The Schall Law Firm Encourages DENTSPLY SIRONA Inc Investors To Join The XRAY Probe

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.

News for DENTSPLY SIRONA Stock (XRAY)